Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
| Status: | Archived |
|---|---|
| Conditions: | High Cholesterol, HIV / AIDS, Metabolic |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Immunology / Infectious Diseases, Pharmacology / Toxicology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2009 |
| End Date: | December 2010 |
A Pilot, Open-Label Study of Adjunctive Therapy With Lovaza® in Hypertriglyceridemic, HIV-Infected Subjects Who Switched Protease Inhibitor to Once-Daily Lexiva® 1400mg Plus Norvir® 100mg Plus Optimized Background
In subjects on boosted protease inhibitor (PI)-regimens who have elevated triglycerides, a
switch to fosamprenavir/ritonavir once daily followed by the addition of Lovaza will result
in 30% of patients achieving a reduction in fasting triglycerides < 200 mg /dL while
maintaining virologic suppression.
We found this trial at
1
site
Click here to add this to my saved trials
